Sumitomo Dainippon Pharma (Japan)

Sumitomo Dainippon Pharma (Japan)

Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Sumitomo Dainippon Pharma (Japan), Japan, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

45%


Total
Publications

1.9K


Total Open
Publications

871


Total
Citations

56K


Open Access
Percentage

45%


Total
Publications

1.9K


Total Open
Publications

871


Total
Citations

56K

Wikipedia

Website

download

Breakdown

23% 17% 5% 55%

Publisher Open

23%

Both

17%

Other Platform Open

5%

Closed

55%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0102030405060708090100Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

26%OA Journal

OA Journal 26%

202

Hybrid 28%

215

No Guarantees 46%

354

Other Platform Open

Domain 84%

362

Institution 16%

71

Public 9%

39

Preprint 8%

33

Other Internet 8%

33

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
361
Europe PMC
Domain
168
Semantic Scholar
Public
35
DOI
Other Internet
28
Research Square
Preprint
16
Kyoto University - Kyoto University Research Information Repository
Institution
15
Kobe University - Kobe University Repository Kernel
Institution
13
bioRxiv
Preprint
11
Hokkaido University - Hokkaido University Collection of Scholarly and Academic Papers
Institution
9
University of California - eScholarship University of California
Institution
8
1 / 5

Data updated 7 April 2025

Share

Share

Share